CREBBP and prostate carcinoma: CBP/P300 BRD inhibition has been reported to reprogram cancer cells to reduce proliferation and treatment resistance in many cancer types, but most studies and clinical trials have focused on blood cancers and prostate cancer (21, 22, 65, 66).